Laos Lucius Edition Sotorasibu (AMG510) Price and Drug Overview

Sotorasiib (AMG510), as a targeted drug targeting KRAS gene mutations, occupies an important position in the treatment of non-small cell lung cancer (NSCLC). Among the many versions of generic drugs, sotorasibu produced by Lucius Pharmaceutical Factory in Laos has attracted much attention. The generic drug is highly consistent with the original drug in terms of ingredients, but differs in price and specifications, providing patients with more choices.

Currently, the specifications of the Laos Lucius version of Sotorasibu are120mg*56 tablets/box, and the price is about more than 1,000 yuan (the specific price may be adjusted due to exchange rate fluctuations). Compared with original drugs, its price is more advantageous, reducing the financial burden on patients.

Sotoraxib is an oral, small molecule inhibitor that specifically targetsmutated forms of the KRAS gene product. KRAS gene mutations are found in a variety of cancers, and are particularly common in non-small cell lung cancer. The mutation causes continued production of proteins that stimulate cells to overgrow and form tumors. Sotoraxib effectively blocks the growth and proliferation of tumor cells by binding to and inhibiting these abnormal KRAS gene products.

In clinical trials, sotoraxib demonstrated significant therapeutic effects. For patients with refractory non-small cell lung cancer carrying KRAS G12C mutations, the drug induced objective responses, providing new treatment hope for these patients. The recommended dose is 960 mg orally once daily until disease progression or unacceptable toxicity.

However, like other drugs, sotorasiib has certain side effects. Nearly all patients who receive treatment experience some degree of side effects. Uncommon but potentially serious adverse events include hepatotoxicity, interstitial lung disease, and embryo-fetotoxicity.